"It's incredible, and a big surprise, that the same infection that caused so much devastation can help create a ...

Phase 3 trial results support toripalimab plus chemotherapy as a first-line treatment option for patients with ES-SCLC, researchers say.

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Male sex was also shown to be an independent risk factor for longer hospital stays and increased hospitalization costs at ...

Q3 2024 Earnings Call Transcript November 14, 2024 Affimed N.V. beats earnings expectations. Reported EPS is $-1.03, ...

Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

Lung cancer is the top cause of cancer-related deaths globally, more prevalent in men, and ranks third among women. Both ...

Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative therapeutic ...

Lung cancer is the leading cause of cancer deaths in America, and catching it early is vital. That’s exactly what a low-dose ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

Content by Intermountain Health Regional Communications. Did you know that raising awareness and encouraging screening can ...